Results 31 to 40 of about 2,519 (184)
Bleeding Risk of Anticoagulation Reversal Strategies Before Heart Transplantation: A Retrospective Comparative Cohort Study [PDF]
Journal of Cardiovascular Development and DiseaseHeart transplantation (HT) poses high bleeding risks, especially for patients on anticoagulation. This study evaluates the use of idarucizumab for dabigatran (DBG) reversal compared to vitamin K antagonist (VKA) strategies in HT. A retrospective analysis
Antonio Prieto-Romero +10 more
doaj +2 more sources
Reversal of Dabigatran with Idarucizumab in Acute Subarachnoid Hemorrhage [PDF]
Clinical Practice and Cases in Emergency Medicine, 2017 Dabigatran etexilate mesylate is a direct thrombin inhibitor used for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Jonathan Balakumar +2 more
doaj +2 more sources
Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile [PDF]
Cost Effectiveness and Resource AllocationBackground Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot +5 more
doaj +2 more sources
Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report [PDF]
International Journal of Emergency MedicineDabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli +5 more
doaj +2 more sources
Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
Trauma Case Reports, 2021 Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle +4 more
doaj +1 more source
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
Scientific Reports, 2021 Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed.
Mojca Božič Mijovski +4 more
doaj +1 more source
Cardiology and Therapy, 2023 Introduction Idarucizumab, a monoclonal antibody fragment that rapidly reverses the anticoagulant effects of dabigatran, was approved in Japan in September 2016, at which time an all-case, postmarketing surveillance (PMS) study was initiated to collect ...
Masahiro Yasaka +7 more
doaj +1 more source
Vascular Health and Risk Management, 2016 Tiffany Y Hu,1 Vaibhav R Vaidya,2 Samuel J Asirvatham2,31Mayo Medical School, 2Division of Cardiovascular Diseases, Department of Internal Medicine, 3Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USAAbstract: Novel oral ...
Hu TY, Vaidya VR, Asirvatham SJ
doaj +1 more source
Medicina, 2023 Background and Objectives: The effectiveness and safety of idarucizumab for the reversal of the effects of dabigatran have been proven. However, there remains a paucity of literature comprehensively investigating outcomes in real-world patients.
Jhih-Wei Dai +3 more
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2022 Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors.
Alex C. Spyropoulos MD +6 more
doaj +1 more source